Diagnostic Testing for
    Alzheimer’s Disease

    Home
    Industry-Leading Diagnostic Testing for Alzheimer’s Disease

    We empower healthcare professionals with cutting-edge solutions for neurological testing, focusing on early, accurate detection of neurodegenerative diseases—most notably Alzheimer’s disease. Our new ALZpath™ p-Tau 217 blood test offers unmatched diagnostic accuracy and is now available for clinical use in our CAP/CLIA-certified laboratory.

    Why Early Detection Matters

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder caused by the buildup of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau (p-Tau). These changes can begin years before symptoms appear, making early biomarker-based detection critical for timely diagnosis and care.

    p-Tau 217: A Breakthrough Biomarker

    Tau proteins help stabilize nerve cell structures, but when they become hyperphosphorylated, they aggregate into tangles that disrupt brain function. Among tau isoforms, p-Tau 217 has proven to be one of the most reliable indicators of Alzheimer’s disease. Elevated p-Tau 217 levels in plasma and cerebrospinal fluid (CSF) strongly correlate with disease progression and align closely with amyloid and tau PET imaging results.

    About the ALZpath™ p-Tau 217 Test

    Our ALZpath™ p-Tau 217 assay matches the performance of CSF-based testing while offering the convenience of a blood draw. In clinical validation studies, it achieved high diagnostic accuracy in identifying amyloid PET-positive individuals (AUC = 0.932).

    Test Specifications:

    • Sample Type: EDTA plasma
    • Turnaround Time: 3–10 business days
    • Laboratory Certification: CAP/CLIA-certified

    Alzheimer's Disease Panel

    Includes three tests: p-Tau 217, NfL, and GFAP, to provide a more complete picture of brain health.
    • p-Tau 217 reflects Alzheimer’s-specific brain changes.
    • NfL shows overall nerve cell damage from many neurological conditions.
    • GFAP detects early brain inflammation or injury.
    Together, they help distinguish Alzheimer’s disease from other causes of cognitive decline, identify early changes before symptoms worsen, and improve diagnostic accuracy and monitoring over time.

    Plasma Phosphorylated Tau 217 (p-Tau 217)

    When Tau protein becomes hyperphosphorylated (p-tau), it can clump into tangles that damage and kill brain cells. The p-Tau 217 form is important as its levels rise in both blood and spinal fluid during Alzheimer’s disease, making it a useful marker for diagnosis.

    Plasma Neurofilament Light Chain (NfL)

    It measures NfL levels in plasma to help evaluate neurological disorders. NfL is a general marker of nerve cell damage, and higher levels are linked to conditions such as Alzheimer’s disease, ALS, multiple sclerosis, frontotemporal dementia, and traumatic brain injury.

    Plasma Glial Fibrillary Acidic Protein (GFAP)

    GFAP is a protein released by brain cells (astrocytes) when the brain is under stress from injury, inflammation, or disease. Higher blood GFAP levels can indicate early brain changes and are often seen in Alzheimer’s, even in mild cognitive impairment.
    GFAP can be elevated in Alzheimer’s and other brain conditions like stroke, trauma or neurodegenerative diseases. When combined with p-Tau, it can improve the accuracy of diagnosing or predicting Alzheimer’s
    Alzheimer's Disease Requisition Form

    Accessible, Patient-Focused Testing

    Our services are designed for both patients and healthcare providers, with a streamlined ordering process that ensures efficiency, clarity, and convenience from start to finish.

    Together, we can change the future of Alzheimer’s diagnosis—making early detection more accurate, accessible, and actionable.
    Book Your Appointments
    Book Your Appointments